PER® Precision Medicine Symposium: An Illustrated Tumor Board | Conference

Tailoring Therapy for Breast Cancer in 2021: Examining and Applying Clinical Lessons

September 21st 2021

Personalized medicine has come to the forefront of breast cancer management, with genomic tools being utilized to avoid unnecessary chemotherapy in those with early-stage disease, PARP and PI3K inhibitors improving outcomes for those who harbor select mutations, and the emergence of highly active targeted agents shaking up the HER2-positive paradigm.

Dr. Goy on the Importance of Refined Decision Making With Precision Medicine

September 20th 2021

Andre H. Goy, MD, discusses the importance of refined decision making with precision medicine.

Dr. Marshall on the Importance of Molecular Profiling When Utilizing Precision Medicine

September 20th 2021

John L. Marshall, MD, discusses the importance of molecular profiling when utilizing precision medicine.

Dr. Levy on Overcoming Osimertinib Resistance in EGFR-Mutant NSCLC

September 20th 2021

Benjamin P. Levy, MD, discusses potential strategies to overcome resistance to osimertinib in EGFR-mutant non–small cell lung cancer. 

Goy Taps Into the True Potential of Precision Medicine in Oncology

September 18th 2021

Current approaches to precision medicine in oncology have been fruitful, but require better integration and utilization of available resources to inform sustainable and effective drug development and clinical care, according to Andre Goy, MD.

Novel Immunotherapy Options Prompt Paradigm Shift in NSCLC Treatment

September 18th 2021

A shift in the NSCLC treatment paradigm came in the form of immunotherapy, which has since seen significant progress—mostly in the past decade.

Dr. Petrylak on Pivotal PARP Inhibitor Trials in mCRPC With DNA Repair Mutations

September 28th 2020

Daniel P. Petrylak, MD, discusses the pivotal trials that have led to the regulatory approvals of the PARP inhibitors olaparib and rucaparib in patients with metastatic castration-resistant prostate cancer and DNA repair mutations.

Dr. Levy on the Role of Dabrafenib/Trametinib in BRAF V600E-Mutant NSCLC

September 28th 2020

Benjamin P. Levy, MD, discusses the role of the combination of dabrafenib and trametinib in BRAF V600E-mutant non–small cell lung cancer.

Precision Medicine Picks up Pace Across Oncology

September 28th 2020

Andre Goy, MD, MS, discusses how matching the right treatment with the right patient resides at the heart of precision medicine, but with continued interest in pursuing the molecular milieu of cancers, precision medicine has the potential to better inform pre- and post-cancer interventions as well.

Precision Medicine Challenges Deepen in DLBCL As Subtypes Emerge

September 28th 2020

Despite efforts to advance the precision oncology portfolio for patients with diffuse large B-cell lymphoma by categorizing subtypes of the molecularly heterogenous disease, developing treatment routes for these alternate forms presents an uphill battle.

Leveraging Immunotherapy and Targeted Therapy for Cure in Lung Cancer

September 26th 2020

Efforts to leverage targeted therapy and immunotherapy, which have been approved modalities in advanced non–small cell lung cancer, are leading to improved survival in patients with advanced and earlier-stage disease.

Dr. Goy on Updates in Precision Medicine in Oncology

September 26th 2020

Andre Goy, MD, MS, discusses updates in precision medicine. 

Vokes Voices How to Use Genomics to Predict Response to Checkpoint Inhibitors in Cancer

September 26th 2020

Natalie I. U. Vokes, MD, discusses the rise of predictive genomic biomarkers in oncology.

Today’s Molecular Profiling Efforts Will Define the New Decade of GI Cancer Management

September 26th 2020

Over the past decade in gastrointestinal cancer treatment, the acknowledgement that cancer is heterogeneous and likely polyclonal has prompted a shift from gene testing for some patients, to many patients.

Dr. Levy on the DFS Benefit Achieved With Adjuvant Osimertinib in EGFR+ NSCLC

September 25th 2020

Benjamin P. Levy, MD, discusses the disease-free survival benefit with adjuvant osimertinib in the phase 3 ADAURA trial.

Dr. Vokes on Investigative Biomarkers of Response to Checkpoint Inhibitors in Cancer

September 25th 2020

Natalie I. U. Vokes, MD, discusses investigative biomarkers of response to checkpoint inhibitors in the field of oncology.